Madrigal Pharmaceuticals, INC Form 4 insider transactions

Director Kenneth Bate of Madrigal Pharmaceuticals received restricted stock units and stock options on June 25, 2024, according to a Form 4 filing.

Director James M. Daly of Madrigal Pharmaceuticals received restricted stock units and stock options on June 25, 2024, according to a Form 4 filing.

Director Richard S. Levy of Madrigal Pharmaceuticals received a grant of restricted stock units and a stock option on June 25, 2024.

Director Paul A. Friedman reported changes in beneficial ownership of Madrigal Pharmaceuticals stock, including the acquisition of restricted stock units and stock options.

Baker Bros. Advisors and related entities report acquisition of restricted stock units and stock options in Madrigal Pharmaceuticals, reflecting compensation for board service.

Robert E. Waltermire, Senior VP of Madrigal Pharmaceuticals, exercised stock options and sold shares on June 14, 2024.

Robert E. Waltermire, Senior VP of Madrigal Pharmaceuticals, exercised stock options and sold 2,000 shares of common stock on June 12, 2024.

Director Fred B. Craves reported gifting shares of Madrigal Pharmaceuticals stock on June 11, 2024.

Robert E. Waltermire, Senior VP, Chief Pharma Dev. at Madrigal Pharmaceuticals, sold 1,036 shares of common stock at a price of $231.34 on May 21, 2024.

Director Fred B. Craves exercised stock options and sold shares of Madrigal Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Rebecca Taub, a Director, President of R&D, and CMO at Madrigal Pharmaceuticals, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Director Paul Friedman exercised stock options and sold shares of Madrigal Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Rebecca Taub, a key executive at Madrigal Pharmaceuticals, executed multiple sales of company stock between April 3rd and April 5th, 2024, while also exercising stock options.

Paul Friedman, a director at Madrigal Pharmaceuticals, executed stock options and sold shares of common stock between April 3rd and April 5th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Richard S. Levy exercised stock options and sold shares of Madrigal Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Director Kenneth Bate exercised stock options and sold shares of Madrigal Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Director James Daly exercised stock options and sold shares of Madrigal Pharmaceuticals common stock under a pre-arranged Rule 10b5-1 trading plan.

Baker Bros. Advisors LP reports the acquisition of warrants to purchase common stock in Madrigal Pharmaceuticals through an underwritten offering.